Jacobson Mark L.
Jacobson Mark L., COO, reported a transaction classified as exercise at Axsome Therapeutics, Inc. involving 10000.000000 shares for an estimated $129500.00. Reported holdings after the transaction were 10000.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Sep 03, 2026
- Filing date
- Sep 03, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
AXSM price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001193125-26-382277 Common Stock
- Transaction date
- Sep 03, 2026 Filed Sep 03, 2026, 11:09 PM · 0d delay
- Shares
- 10,000 sh $12.95 per share
- Estimated value
- $129k Computed from shares × price
- Holdings after
- 10,000 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Operating Officer
- F1
Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
- F2
Such transaction was pursuant to a pre-approved 10b5-1 plan.
- F3
Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- F4
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.
0 other transactions
0 recent txs